Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Archive for July, 2014

CREW Alleges That Adam Feuerstein is Involved in Stock Manipulation Scheme in Regard to Northwest Biotherapeutics

Citizens for Responsibility and Ethics in Washington (CREW) have gone after Adam Feuerstein of The They have accused him of taking part in a stock manipulation scheme in regard to Northwest Biotherapeutics and other biotechnology companies. I went to their website to get an idea of who they are. They refer to some of […]

Inovio: Successful Phase 2 Trial in Cervical Dysplasia Provides Proof of Concept for the Technology Base (INO, $12.98, Neutral, Subscribers Only)

Inovio’s Immunotherapy Technology Base Over two decades ago, the creation of naked DNA vaccines gave the promise of a significant advance in the development of both therapeutic and preventative vaccines. The concept was to incorporate genes in a plasmid that would express certain antigens.  These would then trigger an effective immune response that could be […]

Northwest Biotherapeutics: Market Research Firm Evaluate Pharma Projects 2020 Worldwide Sales of $2.0 billion for DCVax-L (NWBO, Buy, $5.92)

One of the basic charges made against me by Richard Pearson and other short sellers is that they maintain that DCVax-L is a hoax and no credible analyst thinks that the product has any possibility for success. Pearson maintains that there is only a small group of paid promoters who have anything positive to say […]

My Rebuttal to Richard Pearson’s Attack Article on Me Is Now On Seeking Alpha

After a week of effort in trying to post a rebuttal to Richard Pearson’s attack article on me, I finally got Seeking Alpha  to agree to publish it after three rejections. You can follow the comments on Seeking Alpha at this link I have been doing some work on Pearson to try to find out […]

Agenus: Encouraging Data on Prophage, But What is the Path Forward (AGEN, Buy, $3.28)

Introduction On July 1, Agenus announced results from a non-randomized, phase 2 study of its therapeutic cancer vaccine Prophage in newly diagnosed glioblastoma multiforme patients. This was a 46 patient trial conducted at eight centers. All patients received Prophage plus standard of care (SOC) which is gross total resection to surgically remove as much of […]

Antares; My View of How Otrexup and Medac’s New Product Rasuvo May Compete (ATRS, Buy, $2.54)

Investors Are Concerned About Rasuvo’s Impact on Otrexup Investors have been concerned about the potential effect on Otrexup if the private company Medac gains approval for Rasuvo. Both products are device drug combinations that use highly engineered and proprietary auto injectors to administer methotrexate as a sub-cutaneous injection. These products were both developed under the […]

Northwest Biotherapeutics (NWBO, Buy $6.75): Responding to Serious Unsubstantiated Allegations by Richard Pearson

Who Is Richard Pearson? On July 7, I was the subject of a vicious and libelous article that was published on Seeking Alpha by a person named Richard Pearson. As a way of introduction to Pearson, let’s look at his disclosure on his Seeking Alpha articles. He says, “The author (Pearson) currently holds a short […]